Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0449 | 0.265 | 0.5 |
Loa Loa (eye worm) | hypoxia-induced factor 1 | 0.0661 | 0.8475 | 0.8016 |
Loa Loa (eye worm) | hypothetical protein | 0.0717 | 1 | 1 |
Onchocerca volvulus | 0.0353 | 0 | 0.5 | |
Echinococcus multilocularis | jun protein | 0.0449 | 0.265 | 0.5 |
Echinococcus granulosus | jun protein | 0.0449 | 0.265 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0449 | 0.265 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0365 | 0.0338 | 0.5 |
Brugia malayi | hypoxia-induced factor 1 | 0.0661 | 0.8475 | 0.8475 |
Brugia malayi | bZIP transcription factor family protein | 0.0449 | 0.265 | 0.265 |
Schistosoma mansoni | jun-related protein | 0.0365 | 0.0338 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 33 uM | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets | ChEMBL. | 9276015 |
IC50 (functional) | > 33 uM | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets | ChEMBL. | 9276015 |
Inhibition (functional) | > 28 % | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets at a compound conc of 33 uM | ChEMBL. | 9276015 |
Inhibition (functional) | > 28 % | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets at a compound conc of 33 uM | ChEMBL. | 9276015 |
Lysis (functional) | = 0 % | The cell lytic potency at a compound concentration of 33 uM in bovine platelets was determined | ChEMBL. | 9276015 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.